A substantial number of mutations have been identified in voltage-gated sodium channel genes that result in various forms of human epilepsy. SCN1A mutations result in a spectrum of severity ranging from mild febrile seizures to Dravet syndrome, an infant-onset epileptic encephalopathy. Dravet syndrome patients experience multiple seizures types that are often refractory to treatment, developmental delays, and elevated risk for SUDEP. The same sodium channel mutation can produce epilepsy phenotypes of varying clinical severity. This suggests that other factors, including genetic, modify the primary mutation and change disease severity. Mouse models provide a useful tool in studying the genetic basis of epilepsy. The mouse strain background can alter phenotype severity, supporting a contribution of genetic modifiers in epilepsy. Funding: This study was supported by National Institutes of Health grants R01 NS053792 (JAK) and R01 NS084959 (JAK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Introduction
Epilepsy is one of the most common neurological disorders, affecting approximately 50 million people worldwide. Approximately two-thirds of human epilepsies are presumed to have a genetic basis. Voltage-gated sodium channel gene mutations are the most common cause of monogenic epilepsy. Mutations in SCN1A, encoding Nav1.1, result in a broad spectrum of disorders ranging from simple febrile seizures to Dravet syndrome, a severe, infant-onset epileptic encephalopathy with devastating outcomes [1] . Dravet syndrome patients have multiple seizures types that are refractory to treatment, as well as delays of psychomotor and cognitive development and a high risk of sudden unexpected death in epilepsy (SUDEP) [2] .
Within genetic epilepsies, diverse phenotypes often result from identical sodium channel mutations [3] . This suggests that disease severity is influenced by other factors, including genetic modifiers. The genetic basis of epilepsy can be studied using mouse models that recapitulate hallmark features of human epilepsies. Frequently, mutations that result in seizures show strain-dependent phenotype variability, suggesting a contribution of genetic modifiers in epilepsy [4] . Heterozygous deletion of mouse Scn1a models features of Dravet syndrome, including spontaneous seizures, thermal seizure sensitivity, cognitive deficits, and increased mortality [5, 6] . Interestingly, expressivity of the Scn1a +/-phenotype is highly strain-dependent. When the Scn1a +/-mutation is maintained on the 129S6/SvEvTac (129) strain, 129. ) offspring exhibit spontaneous seizures and 75% mortality by 8 weeks of age [7] . We previously mapped several Dravet syndrome modifier (Dsm) loci that influence the strain-dependent difference in survival [7] .
Scn1a
In the current study, we used interval-specific congenic (ISC) strains to confirm and fine map the Dsm1 locus on chromosome 5. We then performed candidate gene analysis using an RNA-Seq approach, and identified Gabra2 as a high priority candidate gene. Further evaluation of Gabra2 by expression analysis and pharmacological manipulation support Gabra2 as a putative modifier gene that influences survival in the Scn1a +/-Dravet model.
Results

Fine Mapping of Dsm1 with Interval Specific Congenic Strains
Inheritance of B6 alleles in Dsm1 increased the risk of early death in Scn1a +/-mice [7] . Low resolution mapping identified the Dsm1 1.5 LOD support interval as 27.3-41.3 cM on chromosome 5, with a peak at 34 cM [7] . To refine the Dsm1 map interval, five interval specific congenic (ISC) lines were generated with varying 129-derived chromosome 5 segments within Dsm1 on a congenic B6 background ( Fig 1A) . Candidate Gene Identification by RNA-Seq
The Dsm1 locus was narrowed to a 9 Mb region that contains 109 known and predicted genes, of which 40 are known to be expressed in the brain (Fig 2A) . Within that interval, we identified four genes with non-synonymous coding sequence differences: Phox2b, Tmem33, Slc30a9, and Fryl. (Table 1 ). All resulting amino acid differences were predicted to be tolerated by SIFT [8] . Table) . Nsun7 is a putative RNA methyltransferase that when mutated, leads to reduced sperm motility in humans and mice [9, 10] . Bend4, or BEN domain containing 4, is of unknown function. Gabra2 encodes the GABA A receptor α2 subunit, which has previously been associated with addiction and dependence [11] [12] [13] . Considering the importance of GABA signaling in epilepsy and reported dysfunction in GABAergic signaling in Dravet syndrome [14] [15] [16] , Gabra2 was identified as the top candidate modifier gene at Dsm1. Expression of Gabra2 was significantly elevated in wildtype 129 mice compared to [129XB6]F1 mice (Fig 2B) .
Candidate Gene Expression Analysis
We further evaluated forebrain Gabra2 transcript and protein expression in ISC-D mice carrying homozygous 129/129, heterozygous 129/B6 or homozygous B6/B6 alleles in Dsm1. We used digital droplet RT-PCR (ddRT-PCR) to evaluate transcript expression of Gabra2, as well as expression of other GABA A receptor genes located within Dsm1, including Gabra4, Gabrb1 and Gabrg1. Gabra2 expression was significantly different between all genotypes (F 2,15 = 206.4, p<0.0001). We observed the highest levels of Gabra2 transcript with homozygosity for 129 alleles in Dsm1, intermediate levels with heterozygosity, and the lowest levels with B6 homozygosity ( Fig 3A) . Transcript expression of the other Gabr genes in the interval did not differ between genotypes (S1 Fig). Relative GABRA2 protein expression determined by immunoblotting correlated with the transcript levels, showing the highest expression with homozygous 129 alleles in Dsm1, intermediate with heterozygous alleles, and lowest with B6 homozygosity ( Fig  3B and 3C ). These results demonstrate that the level of Gabra2 expression is regulated by alleles within the Dsm1 interval, and that high expression of Gabra2 is correlated with the protective allele for Scn1a +/-survival.
Pharmacological Modulation of Gabra2
We used clobazam, an anticonvulsant drug that has preferential affinity for the GABRA2 subunit [17] [18] [19] , as a pharmacological tool to further evaluate Gabra2 as a candidate modifier gene. Both Dravet syndrome patients and F1.Scn1a +/-Dravet mice experience seizures triggered by hyperthermia. We evaluated the effect of clobazam on survival and hyperthermia seizure threshold in F1.Scn1a +/-mice. Beginning at P18, F1.Scn1a +/-mice were fed either chow containing clobazam (320 mg per kg of chow; estimated dosage 40 mg/kg/day) or control chow, and survival was monitored to 30 days of age. This dose of clobazam, selected to achieve plasma concentrations within the human therapeutic range, was not sufficient to provide protection against survival. We used the hyperthermia-induced seizure assay to perform an acute dose-response study. Between P14-16, F1.Scn1a increased GTC seizure thresholds to 43.0°C (p < 0.0022) and 42.9°C (p < 0.0079), respectively. To ensure plasma concentrations of clobazam reflected the human therapeutic range (0.1-0.4 μg/mL), plasma samples were assayed by HPLC. The commonly cited clobazam rodent dose of 30 mg/kg [20] [21] [22] resulted in an average plasma concentration that was 15 times higher (5.84 ug/mL) than the human therapeutic range, while the 1 mg/kg dose resulted in an average plasma concentration (0.16 ug/mL) within the range. Plasma concentrations were below the detection limit of the HPLC assay following the 0.3 mg/kg dose.
Discussion
Candidate gene and expression analysis, along with pharmacological testing, identified Gabra2 as a putative modifier gene that influences survival in the Scn1a +/-Dravet mouse model. Considering the significance of GABAergic pathways in relation to epilepsy, strain-specific expression of Gabra2 may differentially influence excitatory/inhibitory balance. Several GWAS studies have demonstrated that human GABRA2 genetic variants are associated with alcohol dependence [23] [24] [25] [26] [27] . However, to date, no GABRA2 genetic variants have been associated with human epilepsy. Altered GABRA2 transcript and protein expression has observed in a number of rodent seizure models and patients with focal cortical dysplasia, tuberous sclerosis and temporal lobe epilepsy, suggesting a potential link between GABRA2 expression and epilepsy [28] [29] [30] [31] [32] . There is evidence for variation in human cortical GABRA2 expression that is associated with a trans eQTL on chromosome Xp11.4 [33] . Our mouse RNA-Seq and expression analysis demonstrated that low Gabra2 expression associated with the B6 allele and correlated with reduced survival in the Scn1a +/-model. Previous work has shown that in some mouse strains, Gabra2 expression is strongly modulated by a cis eQTL that overlaps with Dsm1 and a trans eQTL on chromosome 10 [34] . The difference in Gabra2 expression was maintained when we examined transcript and protein levels in brain tissues from the ISC-D line, which contains 129 alleles only in the minimal interval and is B6 elsewhere in the genome. From this, we infer that Gabra2 expression difference arises from a local eQTL effect within the Dsm1 interval. This is supported by a recent study that demonstrated differential allele expression of Gabra2 transcript in B6/129SF1 mice, with the 129 allele expressed at 2-3 times the level of the B6 allele [35] . Future work will focus on identifying the responsible regulatory variants within the Gabra2 genomic region.
The failure of line ISC-D to reduce seizure frequency in F1.Scn1a +/-mice was not surprising.
As we report here, and have observed in our previous studies, high seizure counts do not correlate with premature death in F1.Scn1a +/-mice. Therefore, we could exclude the survival improvement of the ISC-D line to be a result of altered seizure frequency. GABAergic neurons are found in several brain regions involved in the control of respiration and cardiac activity, and dysfunction in either pathway is believed to be primarily responsible for SUDEP [36] [37] [38] [39] .
Mice with a conditional Scn1a +/-deletion in forebrain GABAergic interneurons experience SUDEP and cardiac dysfunctions similar to the Dravet Scn1a +/-mouse model [40] . When Scn1a +/-was conditionally deleted in the heart, the phenotype was not observed, demonstrating that SUDEP observed in Scn1a +/-mice originates from the central nervous system [40] .
Increased expression of GABRA2 may exert a protective effect by altering autonomic control of cardiac and/or respiratory function and may explain the improved survival observed with 129/ 129 homozygosity in ISC-D. Additionally, GABA A receptor activity plays a pivotal role in neuronal development and altered levels of Gabra2 during development may alter network excitability [41] . Interestingly, clobazam, which has preferential affinity for the GABRA2 subunit, offers some therapeutic benefit in Dravet syndrome patients [17] [18] [19] 42, 43] . In our studies, threshold temperature for hyperthermia-induced seizures was elevated in Scn1a +/-mice treated with supratherapeutic levels of clobazam, while lower doses did not provide significant protection (Phosphosolutions, 822-GA2C; 1:2000) and a mouse monoclonal antibody for mortalin (NeuroMab 75-127; 1:1000) as a loading control. Relative levels were determined by densitometry and expressed as a ratio of GABRA2 to mortalin. Relative GABRA2 protein expression followed the same trend as Gabra2 transcript. Scatter plot data points represent samples from individual mice (n = 5-6 biological replicates). Average values are depicted as a horizontal bar and error bars represent the SD. Statistical comparison between groups was made using ANOVA with Tukey's post-hoc tests.
doi:10.1371/journal.pgen.1006398.g003 from hyperthermia-induced seizures or premature death. The 30mg/kg clobazam dose provided complete protection against hyperthermia-induced seizures, but resulted in plasma levels far above the human therapeutic range, highlighting the necessity of determining drug concentrations in similar studies. Frequently, Dravet syndrome patients are prescribed stiripentol as an add-on treatment to clobazam. In a randomized placebo-controlled study in children with Dravet syndrome, 71% of patients treated with a combination of clobazam and stiripentol experienced a reduction in seizure frequency [44] . Although the mechanism of action for the anticonvulsant benefit of stiripentol is yet to be determined, stiripentol has been identified as an inhibitor of CYP450s, specifically CYP3A4 and more potently CYP2C19, both important for the metabolism of clobazam. In vivo, a significant increase in the plasma concentrations of both clobazam and its active metabolite N-desmethylclobazam has been shown with concomitant stiripentol treatment [45] , suggesting that elevated levels of clobazam may account for some of the therapeutic benefit.
Identification of Gabra2 as a putative modifier gene at the Dsm1 locus furthers our understanding of the genetic basis of Dravet syndrome. This provides information that may help predict the risk of SUDEP and the clinical course of epilepsy due to a sodium channel mutation. Furthermore, modifier genes may suggest new targets for the improved treatment of epilepsy. 
Methods
Ethics Statement
Mice
Scn1a
tm1Kea mice, with deletion of the first coding exon, were generated by homologous recombination in TL1 ES cells (129S6/SvEvTac) as previously described [7] . The 129.Scn1a 
Generation of Interval Specific Congenic (ISC) lines
We generated five ISC lines carrying 129-derived chromosome 5 segments on a B6 background. [129 x B6]F1 progeny were continually backcrossed to B6 to generate congenic lines. Genotyping for chromosome 5 markers was performed at each generation and animals retaining 129 alleles in the Dsm1 interval were propagated. Whole genome and selective genotyping was performed at generations N2-N7 to select breeders with the lowest percentage of 129 alleles in the rest of the genome. All ISC lines were backcrossed to B6 for !N6 generations prior to experiments.
Phenotyping
Dsm1 ISC females were crossed with heterozygous Scn1a +/-males to generate (B6.ISC x 129.
Scn1a +/-
)F1 offspring carrying heterozygous (129/B6) or homozygous (129/129) alleles in Dsm1. Phenotyping was performed similarly to our low-resolution mapping study [7] . Mice were ear-tagged at P12-14. At P21, mice were weaned into holding cages containing four to five mice of the same age and sex. Wild-type littermates were included in all holding cages. Survival was monitored to 8 weeks of age. During that time, all mice were monitored daily for general health and any mouse visibly unhealthy (e.g. underweight, dehydrated, poorly groomed, or immobile) was euthanized and excluded from the study. The focus of the study was sudden and unexpected death in the Scn1a +/− mice occurring in otherwise healthy appearing animals.
We used continuous video monitoring to determine GTC seizure frequency in Scn1a +/-mice with homozygous or heterozygous alleles in ISC-D mice. At P20, mice were placed in a recording chamber and video was captured using a Day/Night camera (Samsung SCB5003) equipped with an infrared lens (Tamron 13FG04IRSQ) and saved to a DVR (Samsung SRD-876D). During recording, mice had ad libitum access to food and water, and were maintained on a 14:10 light-dark cycle. Video records were analyzed offline by an observer blinded to genotype. We validated use of video capture for seizure evaluation in Scn1a +/-mice in a preliminary study. Behavioral GTC seizures were correlated with electroencephalographic seizures using video-electroencephalography (EEG) monitoring as previously described. On P16, F1.Scn1a
+/-mice were implanted with prefabricated headmounts (Pinnacle Technology, Inc., Lawrence, KS, USA) and mice were allowed to recover for >72 hours. Continuous video-EEG data monitoring was performed from P20-P26. Data were acquired and analyzed with Sirenia software (Pinnacle Technology, Inc.). Electrographic GTC seizure activity was scored manually using video-EEG data. Separately, behavioral GTC seizures were counted using only the video record.
There was perfect agreement between the video-EEG and video-only results (κ = 1.0; n = 25 mice; 39 seizures), validating video recording as a reliable method for measuring GTC seizure frequency in Scn1a +/-mice.
Genotyping
DNA was prepared from tail biopsies using the Gentra Puregene Mouse Tail Kit according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). Scn1a genotype was determined by multiplex PCR as previously described [7] . Microsatellite genotyping was performed by analysis of PCR products on 7% denaturing polyacrylamide gels stained with ethidium bromide.
RNA-Seq
Hippocampi were dissected from 129 and [129 x B6]F1 mice at P24. Primary pools were created with tissue from both male (n = 2) and female (n = 2). Total RNA was isolated using TRIzol reagent according to the manufacturer's instructions (Life Technologies). Following RNA isolation, RNA integrity was assessed and all samples had a RIN of ! 7.7. For each strain, three superpooled biological replicates were generated by combining total RNAs from 3-4 primary pools (n = 12-16 mice/superpool). RNA integrity was assessed on the superpool samples and all samples had a RIN of ! 8.1. Samples were processed for RNA-Seq using the TruSeq RNA Library Preparation Kit v2 (Illumina, San Diego, CA, USA). Samples were sequenced on an Illumina HiSeq 4000 at BGI (Hong Kong, China). Three multiplexed lanes of 50-bp single-end sequencing resulted in almost 167 million mapped reads. Base calling and filtering of sequence reads were performed with the Illumina pipeline [46] . Bioinformatic analysis was performed using Tuxedo Tools on the GALAXY platform [47] [48] [49] . Tophat2 aligned reads with Bowtie2 and identified splice junctions [50] . StringTie assembled alignments into transcripts [51] . Cuffmerge and Cuffcompare combined biological replicate transcript files and assigned reference annotations to transcripts [52] . Cuffdiff provided significance values for expressed genes and transcripts [52] .
ddRT-PCR
Forebrain RNA was extracted from P24 ISC-D mice carrying homozygous B6, homozygous 129, or heterozygous alleles. Total RNA was isolated using TRIzol reagent according to the manufacturer's instructions. First-strand cDNA was synthesized from 2 micrograms of RNA using oligo(dT) primer and Superscript IV reverse transcriptase according to the manufacturer's instructions (Life Technologies). First-strand cDNA samples were diluted 1:10 and 5 μl was used as template. Quantitative digital droplet PCR (ddPCR) was performed using ddPCR Supermix for Probes (No dUTP) (Bio-Rad, Hercules, CA, USA) and TaqMan Gene Expression Assays (Life Technologies) for mouse Gabra2 (FAM-MGB-Mm00433435_m1), Gabra4 (FAM-MGB-Mm00802631_m1), Gabrb1 (FAM-MGB-Mm00433461_m1), Gabrg1 (FAM-MGB-Mm00439047_m1) and Tbp (VIC-MGB-Mm00446971_m1). Reactions were partitioned into 20,000 droplets (1 nL each) in a QX200 droplet generator (Bio-Rad). Thermocycling conditions were 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute (ramp rate of 2°C/sec) and a final inactivation step of 98°C for 10 minutes. Following amplification, droplets were analyzed with a QX200 droplet reader with QuantaSoft v1.6.6.0320 software (Bio-Rad). All assays lacked detectable signal in no-RT and no template controls. Relative transcript levels were expressed as a ratio of the gene of interest concentration to Tbp concentration. Statistical comparison between groups was made using ANOVA with Tukey's post-hoc tests. Data are presented as mean ± SD of 5-6 biological replicates.
Immunoblotting
Forebrain membrane proteins were isolated from P24 ISC-D mice carrying homozygous B6, homozygous 129, or heterozygous alleles. Membrane fractions (50 μg/lane) were separated on a 7.5% SDS-PAGE gel and transferred to nitrocellulose membranes. Immunoblots were probed for GABRA2 using a rabbit polyclonal antibody (Phosphosolutions, 822-GA2C) and for Mortalin using a mouse monoclonal antibody (NeuroMab, 75-127). Alexa-conjugated fluorescent secondary antibodies (Jackson ImmunoResearch) were used to detect bound primary antibody using an Odyssey imaging system (Licor).
Hyperthermia Induced Seizures
F1.Scn1a
+/-mice between P14 to P16 received an intraperitoneal injection of 0, 0.3, 1, or 30 mg/kg doses of clobazam solubilized in vegetable oil (10 ml/kg volume). After 15 minutes, each mouse was placed in a cylindrical container and fitted with a RET-3 rectal probe (Physitemp) connected to a heat lamp via a temperature controller (TCAT-2DF (Physitemp) reconfigured with a Partlow 1160+ controller). At 20 minutes post-injection, mouse body temperature was elevated by 0.5°C every two minutes until a maximum of 42.5°C was reached. When a GTC seizure occurred (rearing and falling with forelimb clonus), mice were removed from the container and temperature was recorded. If after 3 minutes at 42.5°C no seizure occurred, the mouse was removed and recorded as a seizure-free.
Clobazam Assay by HPLC
Mice that underwent hyperthermia-induced seizure threshold testing were immediately removed from the assay and anesthetized with isoflurane. Cardiac puncture was performed and whole blood was collected in heparin microtainers (BD365965). Plasma was isolated by centrifugation (9000 x g for 10 minutes at 4°C). Plasma samples (50-100 μL) were spiked with 5 μg/mL prazepam (250 μg/mL in methanol) as an internal standard and vortexed well. Extraction of clobazam and prazepam was achieved by vortex-mixing with diethyl ether (4x volume).
The organic layer was isolated following centrifugation at 2000 rpm for 5 minutes and was evaporated by heating at 75°C. The residue was reconstituted in acetonitrile:20 mM potassium phosphate buffer, pH 7 (42:58, v/v). Clobazam was detected in plasma samples using a HPLC 9 Flexar Binary LC Pump Platform and Flexar UV/Vis Detector (Perkin Elmer, Waltham, MA) with a Polaris C-18A 5 μm column (4.6 x 100 mm; Agilent Technologies, Santa Clara, CA). The mobile phase consisted of acetonitrile and 20 mM potassium phosphate, pH7 (42:58, v/v) with a flow rate of 1.5 mL/min and detection at a wavelength of 228 nm. Quantitative analysis clobazam was performed using a calibration curve (0.05-1.0 μg/mL) by spiking clobazam into blank mouse plasma and preparing as described above. 
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